High-sensitivity C-reactive protein (hsCRP) measures the low-level chronic inflammation load your body is carrying. It is one of the strongest predictors of cardiovascular events available from a routine blood draw — independent of LDL, ApoB, and standard risk factors — and it responds to changes you can actually make.
The Verdict
What hsCRP physically measures
C-reactive protein is made by the liver in response to interleukin-6, a signalling molecule released by immune cells and by fat tissue. It is not specific to any one disease. It is a general readout of how much inflammatory signalling the liver is currently receiving.
That non-specificity is both the strength and the weakness of the test. It captures inflammation from any source, which is why it predicts events well. It also means a raised value tells you that something is inflamed without telling you what. The interpretation work happens after the number arrives.
Standard bands vs the optimal target
| Band | hsCRP | What it indicates |
|---|---|---|
| Optimal | Under 0.5 mg/L | Typical of lean, active, non-smoking adults with good sleep. |
| Low cardiovascular risk (AHA/CDC) | Under 1.0 mg/L | The standard low-risk band used in guideline risk stratification. |
| Average risk | 1.0–3.0 mg/L | The population middle. Average, not healthy. |
| High risk | Above 3.0 mg/L | Roughly doubles cardiovascular event risk relative to the low band. |
| Probably acute | Above 10 mg/L | Usually infection, injury, or a flare. Re-test in 2–4 weeks rather than interpreting it. |
Why the gap matters
Atherosclerosis is an inflammatory process, not simply a plumbing problem. Lipoprotein particles enter the artery wall; the immune response to them determines whether a stable deposit or a rupture-prone plaque forms. Two people with identical ApoB and very different hsCRP are not carrying the same risk.
This has a practical name in cardiology: residual inflammatory risk. Among patients already on a statin with well-controlled LDL, hsCRP remains a strong predictor of future events. Someone sitting at 2.5 mg/L with a perfect lipid panel has an unaddressed risk driver, and the standard panel will never mention it.
What raises hsCRP, ranked by how often it explains a result
| Driver | How often it is the cause | Notes |
|---|---|---|
| Visceral obesity | The most common driver | Abdominal fat secretes IL-6, which drives hepatic CRP production directly. |
| Insulin resistance | Very common, usually alongside the above | Elevated fasting insulin and hsCRP travel together. |
| Smoking and vaping | Common | A dose-dependent effect that reverses over months after quitting. |
| Poor or short sleep, and untreated sleep apnea | Common and under-recognized | Apnea in particular sustains elevation that diet and exercise will not fix. |
| Periodontal disease | Common, frequently missed | Chronic gum inflammation is a genuine systemic source. A dental exam is a cheap test. |
| Oral estrogen | Universal in users | Oral estradiol and combined oral contraceptives raise CRP two- to three-fold via first-pass liver effects. |
| Autoimmune and inflammatory conditions | Situational | Rheumatoid arthritis, lupus, and inflammatory bowel disease produce sustained elevation. |
| Recent intense exercise, infection, or injury | Transient | Real but temporary. It invalidates the reading rather than describing your baseline. |
What lowers hsCRP
| Intervention | Typical effect | Notes |
|---|---|---|
| Losing visceral fat | Large — often 30–60% | The single most effective intervention. Waist reduction tracks the CRP fall closely. |
| Treating sleep apnea | Moderate to large where present | Often the reason an otherwise healthy person cannot get below 2 mg/L. |
| Statins | 15–40% | An anti-inflammatory effect independent of lipid lowering. |
| Mediterranean-style eating | Moderate | Consistent across trials; effect builds over months rather than weeks. |
| Regular aerobic exercise | Moderate | Measured at rest. Chronic training lowers baseline even though single sessions raise it acutely. |
| Treating gum disease | Small to moderate | Periodontal treatment measurably reduces hsCRP in trials. |
| Omega-3 at 2–4 g EPA/DHA daily | Small to moderate | Dose to an omega-3 index above 8% rather than to a capsule count. |
| Colchicine 0.5 mg daily | Moderate | Prescription. Reduced cardiovascular events in secondary-prevention trials. Not a general wellness intervention. |
How and when to test
- Test at least 48–72 hours after intense training. A marathon or a hard eccentric session can raise hsCRP many times over for several days. Endurance events can take a week to clear.
- Do not test during or within 2–4 weeks of an infection, including a minor cold, a dental procedure, or a vaccination reaction.
- Wait 4–6 weeks after surgery or any injury.
- Fasting is not required. hsCRP is stable across the day and is not affected by meals.
- Test twice, two weeks apart, and use the lower value. Within-person variability is high enough that a single reading can mislead.
- If the result is above 10 mg/L, do not interpret it. Repeat once the likely acute cause has resolved. If it stays above 10 with no explanation, that needs a physician.
What it means in combination
- High hsCRP + high ApoB: inflamed wall plus high particle exposure. This combination carries higher event risk than either marker alone, and usually justifies a tighter ApoB target.
- High hsCRP + high HOMA-IR + large waist: the visceral-fat pattern. One cause explains all three, and treating it moves all three.
- High hsCRP + normal lipids on a statin: residual inflammatory risk. The remaining work is inflammatory, not lipid.
- High hsCRP + low omega-3 index: a correctable nutritional contributor sitting on top of whatever else is driving it.
- High hsCRP + high ferritin + joint symptoms: points toward an autoimmune or rheumatologic process rather than a metabolic one. This needs a rheumatology-oriented workup.
- Persistently high hsCRP with a normal weight and good habits: think periodontal disease, sleep apnea, or an occult inflammatory condition before assuming the number is a fluke.
When a result warrants seeing a physician
- hsCRP above 10 mg/L on two separate draws with no obvious acute cause.
- hsCRP above 3 mg/L that does not improve after three to six months of genuine lifestyle change.
- Elevation alongside unexplained weight loss, fever, night sweats, or persistent joint pain and morning stiffness.
- Elevation with a family history of early cardiovascular disease, which strengthens the case for a coronary calcium score.
- Elevation with loud snoring or witnessed apneas, which warrants a sleep study rather than another supplement.
Frequently Asked Questions
What is a good hsCRP level?
Optimal is under 0.5 mg/L. Standard cardiovascular risk stratification uses under 1.0 as low, 1.0–3.0 as average, and above 3.0 as high. A result above 10 mg/L usually reflects acute infection or injury and should be re-tested 2 to 4 weeks after the event resolves rather than acted on.
What raises hsCRP?
Ranked by how often each explains a result: visceral obesity, insulin resistance, smoking, poor sleep and untreated sleep apnea, periodontal disease, oral estrogen, and autoimmune conditions. Recent intense exercise, infection, and injury raise it transiently — those invalidate the reading rather than describing your baseline.
What lowers hsCRP?
Losing visceral fat has the largest effect, often 30–60%. Treating sleep apnea matters greatly where it is present. Statins lower it 15–40% independent of their lipid effect. Mediterranean-style eating, regular aerobic training, treating gum disease, and omega-3 dosed to an index above 8% each contribute. Colchicine at 0.5 mg daily is a prescription option used in secondary prevention.
Is hsCRP the same as CRP?
They measure the same protein at different sensitivities. Standard CRP is designed to detect acute inflammation and typically cannot resolve differences below about 3–5 mg/L. hsCRP measures down to 0.1 mg/L, which is the range that matters for cardiovascular risk stratification. Ordering standard CRP for risk assessment wastes the draw.
Does lowering hsCRP actually reduce risk, or is it just a marker?
There is direct trial evidence that inflammation itself is causal. Canakinumab, a drug that blocks interleukin-1β, lowered hsCRP and reduced cardiovascular events without changing cholesterol at all. Colchicine trials in secondary prevention showed the same direction. That is stronger evidence than most biomarkers have, though the drugs involved are not used for general prevention.
How many times should I test it?
Twice, ideally two weeks apart, and use the lower of the two. Within-person variability is high — a single hsCRP can differ substantially from the same person's value a fortnight later. Basing a treatment decision on one draw is how people end up treating a forgotten cold.